Ambruticin (W7783) was evaluated in vivo in mice subacutely or nonlethally infected with Histoplasma capsulatum. Results were compared with those obtained with amphotericin B, the drug of choice in human histoplasmosis. In one experiment, ambruticin was shown to be capable of curing infected animals as evidenced by totally negative liver and spleen cultures obtained when mice were sacrificed after 4 weeks of oral treatment with 150 mg of drug per kg per day. The 50% cure dose for ambruticin was between 75 and 150 mg/kg per day; the 50% cure dose for oral amphotericin B in this experiment was between 1.56 and 6.25 mg/kg per day. In a second experiment, both oral ambruticin (150 mg/kg per day) and oral amphotericin B (25 mg/kg per day) were again curative, but to a lesser degree than in the first experiment. Biological cures were obtained with both drugs after 3 and 4 weeks of treatment but not after 2 weeks.
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Ambruticin (W7883) has been shown to be a relatively broad-spectrum antifungal agent active in vitro against a variety of filamentous and dimorphic fungal pathogens (4) (5) (6) . It already has been shown to be active in vivo in mice experimentally infected with Coccidioides immitis and, moreover, capable both of protecting experimental animals against infection with this organism and of producing biological cures (1, 2) . The studies to be reported here compared the in vivo efficacy of orally administered ambruticin with that of orally administered amphotericin B in mice experimentally infected with Histoplasma capsulatium. Cultural studies. In both experiments, cultural studies were performed on target organs of surviving animals at the end of the treatment period. In these studies, spleens and livers were removed from sacrificed survivors, placed in 3-to 4-nil volumes of saline contained in plastic bags, and squashed to produce suspensions which were then plated on Mycosel agar (BBL) with added chloramphenicol. Approximately 1 ml, or 25% of each organ suspension, was plated. The inoculated plates were incubated at 28°C until sufficient growth was present to permit accurate mycological identification. Growth was scored on the basis of + (-10 colonies), ++ (10 to 100 colonies), and +++ to ++++ (greater than 100 colonies, or confluent growth with few or no discrete colonies). Identifications for at least one-third of all positive plates from each group of animals were confirmed by microscopic examination.
MATERIALS AND METHODS
In the second experiment, 10 treated, infected mice from each of the two treatment regimen groups as well as the group of placebo-treated mice were sacrificed at the end of each week of treatment. were scored as + to +++, while the corresponding liver cultures were scored as ++ to ++++.
Six of nine animals treated with amphotericin B for 4 weeks were scored as biological cures on the basis of paired negative spleen and liver cultures. The remaining three mice had negative spleen cultures, while cultures of livers were positive, yielding one or two colonies of H. capsulatum per organ. This is in contrast to results from the first experiment in which all animals treated with either 6.25 or 25 mg of amphotericin B per kg per day were culturally negative at the end of 4 weeks of treatment. A similar reduction in efficacy was observed with ambruticin. Two of eight survivor mice treated with ambruticin were scored as biological cures. Three more were negative on culture of spleen but positive on culture of liver, yielding from three to five colonies in two instances and with a score of ++ in the third. Only one animal treated with ambruticin yielded culture results comparable to those seen in the placebo-treated animals. All eight of the surviving placebo-treated animals yielded positive spleen and liver cultures; scores ranged from ++ to ++++ and were greater than those obtained with placebo-treated animals from the first experiment. These results, combined with the lessened efficacy observed with both drugs, suggest that the infection was more severe in the second experiment.
While no attempt was made to make objective records of gross pathology in either experiment, certain correlations between culture results and organ pathology were noted. In the first experiment, little or no hepatomegaly or splenomegaly was noted in mice receiving the highest doses of ambruticin, and little was seen in mice receiving the next lower dose. Similar observations were noted in mice treated with amphotericin B. Similarly, whereas some organ enlargement was observed during the first 2 weeks of the second experiment in mice receiving both drugs, none was observed in mice sacrificed at the end of the experiment.
DISCUSSION The results presented here show conclusively that orally administered ambruticin was effective in vivo both in reducing the number of viable cells of H. capsulatum in tissues of infected mice and in curing infected mice when administered in sufficient amounts. This activity, however, was not comparable to that of orally administered amphotericin B in similarly infected mice.
Data from the first experiment indicated that the 50% cure dose of ambruticin was in excess of 75 mg/kg per day. Blood levels determined in selected animals some 7 h after their last treatment with ambruticin indicated that those mice receiving the top two doses of ambruticin, 75 and 150 mg/kg per day, had ambruticin levels of between 6 and 16 ,ug/ml; the average level in mice receiving 150 mg/kg per day was 11.2 jig/ml. All other doses yielded no detectable blood levels (S. M. Ringel, personal communication). Historically, it is important to note that amphotericin B administered orally at a dose of 50 mg/kg per day was originally found by others to be curative in mice infected with H. capsulatum as well as capable of providing blood levels in treated animals in the range of 0.4 to 0.5jLg/ml (3) .
Together, the high 50% cure dose of ambruticin in these experiments and the absence of detectable blood levels of ambruticin in mice receiving lower doses of the drug indicate that the optimal dose for this drug has yet to be determined. Apart from this problem of adequate dosage, one fact remains clear: ambruticin is capable of curing animals experimentally infected with H. capsulatum. This, together with similar data for C. immitis (1, 2) , suggests that this drug may become an important and chni- 
